MRM Health has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) ...

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases ...

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

How Does Zeposia Work for UC? UC causes irritation, inflammation, and ulcers in the lining of your large intestine (colon). UC is classified as mild, moderate, or severe, depending on your symptoms.

At five years old, I woke up from a colonoscopy completely unaware that my life was about to change forever. A diagnosis of ulcerative colitis awaited me and would alter my future in ways I couldn’t ...

A new cohort study from Northern Denmark finds that mild-onset Crohn's disease (CD) has worse 10-year probability of progression to moderate-severe disease, at 53%, than that of mild-onset ulcerative ...

Greater background mucosal inflammation was associated with poorer survival outcomes in patients with ulcerative colitis who ...

MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis: Ghent, Belgium Saturday, January 10, 2026, 16:00 Hrs [IST] MRM ...

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...